Нош-Бра®
Producer: CJSC Bryntsalov-A Russia
Code of automatic telephone exchange: A03AD02
Release form: Liquid dosage forms. Solution for injections.
General characteristics. Structure:
Active ingredient: 40 mg of Drotaverinum of a hydrochloride in 2 ml of solution (1 ampoule).
Excipients: sodium pyrosulphite, alcohol, water for injections.
Pharmacological properties:
Pharmacodynamics. Myotropic spasmolysant. On chemical structure and pharmacological properties it is close to a papaverine, but possesses stronger and long action. Reduces receipt of calcium ions in smooth muscle cells (inhibits phosphodiesterase, leads to accumulation of intracellular tsAMF). Reduces a tone of unstriated muscles of internals and a peristaltics of intestines, expands blood vessels. He influences the autonomic nervous system, does not get into the central nervous system.
Existence of direct influence on smooth muscles allows to use as a spasmolysant in cases when drugs from the M-holinoblokatorov group are contraindicated (closed-angle glaucoma, a prostate hyperplasia).
At parenteral administration effect of drug is shown in 2-4 min. The maximum effect occurs in 30 min.
Pharmacokinetics. It is evenly distributed on fabrics, gets into smooth muscle cells. Communication with proteins of plasma - 95-98%. Elimination half-life 2-4 hours. It is generally removed by kidneys, to a lesser extent with bile. Does not get through a blood-brain barrier.
Indications to use:
Spasm of smooth muscles at a chronic gastroduodenit, chronic cholecystitis, a cholelithiasis, a postcholecystectomy syndrome, a peptic ulcer of a stomach and a 12-perstny gut, kardio-and a pylorospasm, a spastic colitis; a spasm of peripheral arterial vessels, brain vessels, renal colic, альгодисменорея, for weakening of reductions of a uterus and a spasmolysis of a neck of uterus at childbirth, when carrying out tool researches.
Route of administration and doses:
Intramusculary or subcutaneously, on 2 - 4 ml of 1 - 3 time a day. Duration of treatment is 1-2 weeks. In need of long treatment pass to administration of drug inside.
In cases when the bystry effect is necessary, 2-4 ml of drug enter intravenously slowly into 10-20 ml 0,9% of isotonic solution of sodium of chloride or 5% of solution of a dextrose.
To children up to 6 years appoint usually in a dose 10-20 mg 1-2 times a day, to children 6 years - in a dose of 20 mg 1-2 times a day are more senior.
Features of use:
It is necessary to avoid driving of the car and occupations other types of activity demanding high concentration of attention, speed of psychomotor reactions during 1 h after parenteral (especially in/in) introduction.
Side effects:
Dizziness, heartbeat, lowering of arterial pressure, feeling of heat, perspiration, allergic skin reactions.
At in introduction - a collapse, AV blockade, arrhythmias, oppression of a respiratory center.
Interaction with other medicines:
At simultaneous use can weaken protivoparkinsonichesky effect of a levodopa.
Strengthens action of a papaverine, Bendazolum and other spasmolysants (including. M-holinoblokato-rov), the lowering of arterial pressure caused by tricyclic antidepressants, quinidine and procaineamide.
Reduces spazmogenny activity of morphine.
Phenobarbital increases expressiveness of spasmolytic action of Drotaverinum of a hydrochloride.
Contraindications:
Individual intolerance; expressed liver, renal, heart failure; AV blockade of the II-III degree, cardiogenic shock, arterial hypotension.
With care - the expressed atherosclerosis of coronary arteries, a prostate hyperplasia, glaucoma, the period of pregnancy and a lactation.
Overdose:
In high doses breaks an auricle - ventricular conductivity, reduces excitability of a cardiac muscle, can cause a cardiac standstill and paralysis of a respiratory center.
Storage conditions:
It is necessary to avoid driving of the car and occupations other types of activity demanding high concentration of attention, speed of psychomotor reactions during 1 h after parenteral (especially in/in) introduction. List B. At a temperature from 15 to 25 °C, in protected from light, the place, unavailable to children. A period of validity - 2 years. Not to apply after the period of validity specified on packaging.
Issue conditions:
According to the recipe
Packaging:
Solution for injections of 2% in ampoules of light-protective glass on 2 ml. 5 ampoules in a blister strip packaging. 1, 2, 3, 4, 5 blister strip packagings together with the application instruction and the scarificator or a knife ampoule in a pack from a cardboard. When using ampoules with notches, a break ring the scarificator or a knife ampoule do not put.